Sugi Predict

Sugi Predict / Compounds / SCHEMBL19207668

SCHEMBL19207668

SCHEMBL19207668

CCOC(=O)CCCc1c(N)cnn1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.42
▸ LMNA P02545 2/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ TNF P01375 7/20 0.40
▸ TBXAS1 P24557 1/20 0.39
▸ CYP4F2 P78329 2/20 0.39
▸ CYP4A11 Q02928 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ ALOX5 P09917 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ CYP4Z1 Q86W10 1/20 0.37
▸ CYP4F11 Q9HBI6 1/20 0.37
▸ CYP4F12 Q9HCS2 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19207565 0.79 TNF (0.45) LMNAALDH1A1TNFTBXAS1SMN1; SMN2
SCHEMBL10965121 0.70 ALDH1A1 (0.49) CYP1A2LMNAALDH1A1TNFTBXAS1
SCHEMBL7451066 0.70 LMNA (0.46) CYP1A2LMNAALDH1A1SMN1; SMN2CYP3A4
SCHEMBL19659008 0.69 DYRK1A (0.33) ALDH1A1
SCHEMBL28370055 0.69 EP300 (0.52) CYP1A2TNF
SCHEMBL28373866 0.69 EP300 (0.52) CYP1A2TNF
SCHEMBL28054281 0.68 CYP1A2 (0.47) CYP1A2ALDH1A1TNFCYP4F2CYP4A11
SCHEMBL4270902 0.68 CYP4F2 (0.64) CYP1A2ALDH1A1CYP4F2CYP4A11SMN1; SMN2
SCHEMBL18366013 0.68 TNF (0.51) CYP1A2ALDH1A1TNFTBXAS1
SCHEMBL1467579 0.67 CYP4F2 (0.58) CYP1A2LMNAALDH1A1CYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388601-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2025-12-25 — — US disclosed
US-12358928-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2025-07-15 — — US disclosed
US-20240150376-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2024-05-09 — — US disclosed
US-20230043400-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2023-02-09 — — US disclosed
US-20230043400-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2023-02-09 — — US disclosed
CN-114437105-A Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2022-05-06 — — CN disclosed
CN-109071504-B Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2022-03-08 — — CN disclosed
US-20200317691-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2020-10-08 — — US disclosed
US-20200317691-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2020-10-08 — — US disclosed
US-10604535-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2020-03-31 — — US disclosed
US-20180022759-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2018-01-25 — — US disclosed
US-20180022759-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2018-01-25 — — US disclosed
US-9815850-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2017-11-14 — — US disclosed
US-9815850-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2017-11-14 — — US disclosed
US-9815850-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2017-11-14 — — US disclosed
WO-2017136727-A2 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. (US) 2017-08-10 — — WO disclosed
WO-2017136727-A2 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. (US) 2017-08-10 — — WO disclosed
US-20170226127-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2017-08-10 — — US disclosed
US-20170226127-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2017-08-10 — — US disclosed
US-20170226127-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2017-08-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388601-A1 Compounds, Compositions and Methods AURKC, WEE2, ERBB2 CYP1A2 783/4885LMNA 581/4885ALDH1A1 3854/4885
US-20200317691-A1 Compounds, Compositions and Methods PIK3CA, PLK1, PIK3CB CYP1A2 3682/4885LMNA 1620/4885ALDH1A1 4405/4885
US-20240150376-A1 Compounds, Compositions and Methods PIK3CA, PLK1, PIK3CB CYP1A2 3682/4885LMNA 1620/4885ALDH1A1 4405/4885
US-12358928-B2 Compounds, compositions and methods PIK3CA, PLK1, PIK3CB CYP1A2 3682/4885LMNA 1620/4885ALDH1A1 4405/4885
US-20230043400-A1 Compounds, Compositions and Methods PIK3CA, PLK1, PIK3CB CYP1A2 3682/4885LMNA 1620/4885ALDH1A1 4405/4885
US-20180022759-A1 COMPOUNDS, COMPOSITIONS AND METHODS PIK3CA, PLK1, PIK3CB CYP1A2 3682/4885LMNA 1620/4885ALDH1A1 4405/4885
US-20170226127-A1 COMPOUNDS, COMPOSITIONS AND METHODS PIK3CA, PLK1, PIK3CB CYP1A2 3682/4885LMNA 1620/4885ALDH1A1 4405/4885
US-10604535-B2 Compounds, compositions and methods PIK3CA, PLK1, PIK3CB CYP1A2 3682/4885LMNA 1620/4885ALDH1A1 4405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.